Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation
Status:
Unknown status
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
HLA-mismatched unrelated donor (MMUD) and HLA-haploidentical donor (Haplo Donor)
hematopoietic stem cell transplantation (HSCT) is associated with increased
graft-versus-host-disease (GVHD) and impaired survival. The chemokine receptor 5 (CCR5)
antagonist maraviroc has immunomodulatory properties potentially beneficial for GVHD control
as it can blockade lymphocyte chemotaxis without impairing T-cell function. The aim of this
study is to evaluate the safety and efficacy of maraviroc combined with standard
graft-versus-host-disease prophylaxis in patients with hematologic malignancies after
allogeneic stem cell transplantation from HLA-Unrelated or HLA-Mismatched Related donors.
Based on the results of our previously small sample study with maraviroc combined with
cyclosporine/tacrolimus and methotrexate for prophylaxis of GVHD, the investigators plan to
perform the clinical trail.
Phase:
Phase 2
Details
Lead Sponsor:
Affiliated Hospital to Academy of Military Medical Sciences